Fmr LLC Sells 1,129,050 Shares of Progyny, Inc. (NASDAQ:PGNY)

Fmr LLC trimmed its holdings in shares of Progyny, Inc. (NASDAQ:PGNY) by 99.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,767 shares of the company’s stock after selling 1,129,050 shares during the quarter. Fmr LLC’s holdings in Progyny were worth $46,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of PGNY. Quarry LP grew its holdings in shares of Progyny by 1,900.0% during the second quarter. Quarry LP now owns 880 shares of the company’s stock valued at $25,000 after buying an additional 836 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Progyny during the 2nd quarter worth about $44,000. Mendota Financial Group LLC purchased a new stake in Progyny during the 3rd quarter valued at about $56,000. Meeder Asset Management Inc. acquired a new position in shares of Progyny in the third quarter valued at about $77,000. Finally, nVerses Capital LLC raised its stake in shares of Progyny by 925.0% in the second quarter. nVerses Capital LLC now owns 4,100 shares of the company’s stock worth $117,000 after purchasing an additional 3,700 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on PGNY. Cantor Fitzgerald restated an “overweight” rating and set a $25.00 target price on shares of Progyny in a research report on Tuesday, October 1st. Jefferies Financial Group decreased their price objective on Progyny from $31.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, September 19th. Truist Financial reaffirmed a “hold” rating and set a $19.00 target price (down from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Leerink Partners decreased their price target on Progyny from $25.00 to $21.00 and set a “market perform” rating for the company in a report on Thursday, September 19th. Finally, Barclays lowered their price objective on Progyny from $30.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Nine investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $25.00.

Progyny Price Performance

Shares of NASDAQ:PGNY opened at $14.53 on Thursday. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of 25.05, a price-to-earnings-growth ratio of 1.64 and a beta of 1.35. The business’s 50 day simple moving average is $15.27 and its 200-day simple moving average is $20.63. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $42.08.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). The business had revenue of $286.63 million for the quarter, compared to analysts’ expectations of $296.85 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. The company’s revenue for the quarter was up 2.0% on a year-over-year basis. During the same period last year, the business earned $0.16 earnings per share. On average, equities analysts anticipate that Progyny, Inc. will post 0.59 earnings per share for the current year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.